Anaplastic Thyroid CancerNCT00280852
Review of Multimodality Management of Anaplastic Thyroid Cancer
An observational study of Anaplastic Thyroid Cancer, run by Alberta Health services at 1 site in Canada.
Trial summary
To describe the outcome of patients with anaplastic thyroid cancer treated with hyperfractionated radiotherapy and concomitant chemotherapy Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Anaplastic Thyroid Cancer
- How many people
- 5 participants
- Where
- 1 siteCanada
- Study dates
- Jan 2006to Jun 2006
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: anaplastic thyroid cancer
Who may be able to join
- anaplastic thyroid cancer treated with multimodality treatment
Who cannot join
- differentiated thyroid cancer
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Retrospective Review of Multimodality Management of Anaplastic Thyroid Cancer
To describe the outcome of patients with anaplastic thyroid cancer treated with hyperfractionated radiotherapy and concomitant chemotherapy
- Conditions
- Anaplastic Thyroid Cancer
- Keywords
- anaplastic thyroid cancer, chemotherapy, radiotherapy
- Medical subject headings
- Thyroid Carcinoma, Anaplastic
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jan 2006 (estimated)
- Study startJan 2006
- Primary completionJun 2006
- Study completionJun 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anaplastic Thyroid CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Retrospective
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alberta Health services
- Sponsor type
- University, hospital or other
- Investigators
- Harold Lau, MD, Principal investigator, Alberta Cancerboard
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00280852
- Sponsor's protocol ID
- 18940
- Status last verified
- Jul 2011
- First submitted
- 20 Jan 2006
- Last updated
- 21 Nov 2011
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Retrospective Review of Multimodality Management of Anaplastic Thyroid Cancer
- ClinicalTrials.gov ID
- NCT00280852
- Acronym / sponsor ID
- 18940
- Conditions
- Anaplastic Thyroid Cancer
- Keywords
- anaplastic thyroid cancer, chemotherapy, radiotherapy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 5 participants (actual)
- Lead sponsor
- Alberta Health servicesUniversity, hospital or other
- Study start
- Jan 2006
- Primary completion
- Jun 2006 (actual)
- Study completion
- Jun 2006 (actual)
- First posted
- 24 Jan 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To describe the outcome of patients with anaplastic thyroid cancer treated with hyperfractionated radiotherapy and concomitant chemotherapy
Study design
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- anaplastic thyroid cancer
Key inclusion criteria (1 listed)
- anaplastic thyroid cancer treated with multimodality treatment
Key exclusion criteria (1 listed)
- differentiated thyroid cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2011.
Related trials for Anaplastic Thyroid Cancer
RecruitingPhase 1
Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial
Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer
Active, not recruitingEarly Phase 1
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
Anaplastic Thyroid Cancer
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruitingPhase 2
Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer
Anaplastic Thyroid Carcinoma, Thyroid Cancer
RecruitingPhase 2
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Thyroid Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Harold Lau, MD principal investigator
Alberta Cancerboard
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Anaplastic Thyroid Cancer, run by Alberta Health services at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Nov 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2011.